Background: The aim was to compare outcomes with remdesivir along with standard care and standard care alone in moderate to severe COVID-19 patients in a tertiary care hospital. Method: A retrospective observational study was conducted by collecting data of moderate to severe COVID-19 patients admitted to covid wards of a tertiary care hospital for a period of six months. Demographic data, information about SpO2 changes, duration of hospitalization, marker status and ventilation status were parameters collected and used to compare between two groups. Results: Total number of patients in this study was 112. Out of which 56 patients who were on Remdesivir with standard care belonged to group A and 56 patients receiving standard care alone belonged to group B. In group A 47 were males and 9 females. In group B 40 were males and 16females. Mean age in group A was 55.98 ± 12.95 (with age range 33 – 84 y)) and in group B 44.11 ± 16.04 (15 - 74 y). Patients in group A showed more presence of comorbidity (55.4%) as compared to group B (17.9%). Mean SpO2 level on day 1 in group A was 87.68 ± 4.27 and in group B 90.00 ± 5.37. On day of discharge mean SpO2 level was 94.63 ± 1.77 in group A and87.68 ± 4.27in group B. Mean length of hospital stay in group A was 4.45 ± 2.36 and 9.86 ± 6.91 in group B. Improvement in marker status for group A was 96.4% and group B 83.9%. Ventilation status was 100% improvement in group A and 94.6% in group B. Conclusion: Remdesivir did not show a significant improvement in management of moderate to severe COVID-19 patients when compared to standard care.